X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STERLING BIOTECH AJANTA PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 28.1 -1.9 - View Chart
P/BV x 11.6 0.1 16,064.6% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
STERLING BIOTECH
Dec-13
AJANTA PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,72011 16,381.0%   
Low Rs1,1033 32,441.2%   
Sales per share (Unadj.) Rs194.626.8 726.0%  
Earnings per share (Unadj.) Rs45.2-15.0 -302.3%  
Cash flow per share (Unadj.) Rs50.3-5.5 -920.7%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.054.9 240.6%  
Shares outstanding (eoy) m88.77267.87 33.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.3 2,797.6%   
Avg P/E ratio x31.2-0.5 -6,717.6%  
P/CF ratio (eoy) x28.1-1.3 -2,205.9%  
Price / Book Value ratio x10.70.1 8,441.9%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,2991,862 6,730.4%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m2,570547 470.0%   
Avg. sales/employee Rs ThNM5,303.3-  
Avg. wages/employee Rs ThNM403.8-  
Avg. net profit/employee Rs ThNM-2,959.0-  
INCOME DATA
Net Sales Rs m17,2757,181 240.6%  
Other income Rs m16643 390.4%   
Total revenues Rs m17,4427,223 241.5%   
Gross profit Rs m5,807947 613.3%  
Depreciation Rs m4512,543 17.7%   
Interest Rs m494,377 1.1%   
Profit before tax Rs m5,474-5,931 -92.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460-1,924 -75.9%   
Profit after tax Rs m4,014-4,007 -100.2%  
Gross profit margin %33.613.2 254.9%  
Effective tax rate %26.732.4 82.2%   
Net profit margin %23.2-55.8 -41.6%  
BALANCE SHEET DATA
Current assets Rs m7,63914,335 53.3%   
Current liabilities Rs m2,71549,809 5.5%   
Net working cap to sales %28.5-494.0 -5.8%  
Current ratio x2.80.3 977.7%  
Inventory Days Days43403 10.7%  
Debtors Days Days79171 46.1%  
Net fixed assets Rs m6,91455,432 12.5%   
Share capital Rs m177268 66.0%   
"Free" reserves Rs m11,44213,935 82.1%   
Net worth Rs m11,72114,701 79.7%   
Long term debt Rs m1499,478 1.6%   
Total assets Rs m14,81473,988 20.0%  
Interest coverage x112.9-0.4 -31,818.3%   
Debt to equity ratio x00.6 2.0%  
Sales to assets ratio x1.20.1 1,201.5%   
Return on assets %27.40.5 5,475.5%  
Return on equity %34.2-27.3 -125.7%  
Return on capital %46.5-6.4 -724.1%  
Exports to sales %55.125.9 212.9%   
Imports to sales %6.00.2 3,535.2%   
Exports (fob) Rs m9,5271,860 512.3%   
Imports (cif) Rs m1,03812 8,504.9%   
Fx inflow Rs m10,4221,860 560.4%   
Fx outflow Rs m1,67825 6,742.5%   
Net fx Rs m8,7441,835 476.5%   
CASH FLOW
From Operations Rs m3,2641,719 189.9%  
From Investments Rs m-2,093-3,148 66.5%  
From Financial Activity Rs m-1,1861,426 -83.1%  
Net Cashflow Rs m-15-3 435.3%  

Share Holding

Indian Promoters % 73.8 33.9 217.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.0 -  
FIIs % 7.6 9.9 76.8%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.0 39.3 43.3%  
Shareholders   20,968 21,482 97.6%  
Pledged promoter(s) holding % 4.4 55.9 7.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALKEM LABORATORIES  PLETHICO PHARMA  FDC LTD.  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Open Flat; Yes Bank Top Gainer(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.31% while the Hang Seng is up 0.07%. The Shanghai Composite is trading up by 0.35%.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 11:30 AM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS